OncoBriefs - Oncology Research News

May 05, 2026

When the Genome’s Bouncer Calls In Sick

When the Genome’s Bouncer Calls In Sick

If TP53 had a social media bio, it would probably say: "Guardian of the genome. Professional chaos stopper. Currently dealing with nonsense." And in some diffuse large B-cell lymphomas, or DLBCL, that chaos stopper is either broken, overwhelmed, or shoved out of the building entirely.

May 05, 2026

When the Tumor Orders Extra Lactate

When the Tumor Orders Extra Lactate

Cancer cells love glycolysis, which is the biochemical version of living on delivery fries and somehow still making it to work. Even when oxygen is around, many tumors burn through glucose and spit out lactate. In osteosarcoma, that matters because lactate is not just metabolic litter. It changes...

May 05, 2026

When the Tumor’s Factory Floor Starts Smoking

When the Tumor’s Factory Floor Starts Smoking

Phrenology once convinced people you could explain the mind by reading bumps on a skull. Cute idea, terrible science. Cancer research has its own version of that mistake when we treat a tumor like it is just a pile of rogue cells and forget the whole miserable workplace around it. This paper argues...

May 04, 2026

Act now and your tumor gets a pregame pep talk, a halftime adjustment, and an encore from immunotherapy - because apparently even head and neck cancer treatment has entered its deluxe box-set era.

Act now and your tumor gets a pregame pep talk, a halftime adjustment, and an encore from immunotherapy - because apparently even head and neck cancer treatment has entered its deluxe box-set era.

Under the sales pitch, though, sits a serious question. A 2026 Journal of Clinical Oncology commentary with the wonderfully shady title Notably Off Key asks whether the applause around the phase 3 KEYNOTE-689 trial might be a little too loud.[1] Translation: yes, perioperative pembrolizumab helped...

May 04, 2026

Not just a missile - now it is urban warfare

Not just a missile - now it is urban warfare

The old ADC story was clean and satisfying: find the cancer cell, dock, enter, release payload, cue dramatic explosion. Tumors, naturally, refused to cooperate. Breast cancers are patchy. One region waves the HER2 flag, another barely mutters it. Some cells internalize drugs nicely, others act like...

May 04, 2026

Pancreatic Cancer’s Weird New Operating System

Pancreatic Cancer’s Weird New Operating System

What makes a cell itself - its DNA, its habits, or the tiny chemical Post-it notes slapped onto the messages it sends all day? That question sits underneath a new April 22, 2026 review in Molecular Cancer, and the answer is delightfully unsettling: in pancreatic cancer, some of the most important...

May 04, 2026

The CT Scan Heist Nobody Saw Coming

The CT Scan Heist Nobody Saw Coming

This study reads like a casino caper: the tumor thinks it has slipped past security in a very average-looking pancreas, and then an AI model strolls in, checks the grain of the wallpaper, and says, "Cute try." In a new Gut paper, researchers built a system called REDMOD that tries to spot...

May 04, 2026

The Liver Sequel Nobody Asked For

The Liver Sequel Nobody Asked For

If this study were a prestige TV drama, the surgeons would spend an entire season pulling off a heroic finale, only for the villain to sneak back into the same apartment building through the side door. That, in plain English, is the problem with colorectal cancer that has spread to the liver: even...

May 04, 2026

When the bouncer works for the bad guys

When the bouncer works for the bad guys

Breast cancer is not one disease wearing one trench coat. It is a whole cast of subtypes, each with its own habits, mood swings, and talent for causing trouble. That is why immunotherapy has looked brilliant in some patients and shrug-worthy in others. The new review by Shichkin and colleagues maps...

May 03, 2026

Colorectal Cancer’s New Passport Stamp Problem

Colorectal Cancer’s New Passport Stamp Problem

Colorectal cancer used to behave like a stew you forgot on the back burner - mostly a problem that showed up later, after years of simmering. Now it is barging into the kitchen early, showing up in younger adults and in more parts of the world, which is less "grandma's slow recipe" and more "who...

May 03, 2026

Duvelisib Just Went Up for Auction, and Relapsed PTCL Finally Heard a Bid Worth Noticing

Duvelisib Just Went Up for Auction, and Relapsed PTCL Finally Heard a Bid Worth Noticing

Going once, going twice, sold - not to miracle hype, but to something much rarer in relapsed peripheral T-cell lymphoma: a result that actually makes oncologists put down their coffee and squint at the screen again.

May 03, 2026

The Tiny Trash Can With a Side Hustle

The Tiny Trash Can With a Side Hustle

If you learned about lysosomes in school, you probably got the discount version: they're the cell's garbage disposals. Which is true in the same way calling a hospital "a building with chairs" is technically true but emotionally unsatisfying.

May 03, 2026

Tim-3, Ferroptosis, and the Liver’s Very Bad Neighborhood

Tim-3, Ferroptosis, and the Liver’s Very Bad Neighborhood

Dispatch from inside the liver: the streets are slick with fat, oxidative stress is drifting through the air like tear gas, and the dendritic cells - the immune system's field reporters - are going down before they can get the message to the CD8 T-cell cavalry.

May 03, 2026

Two patients, one treatment plan, zero room for autopilot

Two patients, one treatment plan, zero room for autopilot

Blood cancers during pregnancy are rare, but rare does not mean simple. It means every decision feels like it was designed by a committee of chaos goblins. The doctor is not just treating a cancer. They are balancing the health of the pregnant patient, the timing of the pregnancy, the type of...

May 03, 2026

Viruses Are Being Asked to Fix the Worst Party in Cancer

Viruses Are Being Asked to Fix the Worst Party in Cancer

The ending first: tumors can sometimes be shoved from "immune dead zone" to "active crime scene" with engineered viruses and cytokine gene therapy. The rewind is where it gets weird, because yes, this means doctors are using carefully modified viruses to make cancer more visible to your immune...

May 03, 2026

When Blood Starts Gossiping About Your Lymphoma

When Blood Starts Gossiping About Your Lymphoma

What is identity, really, if not a pattern that keeps reappearing even when the furniture changes? Cancer, annoyingly enough, seems to agree, because a large B-cell lymphoma can leave behind tiny molecular fingerprints in the bloodstream long before a scan fully settles the argument.

May 03, 2026

When Brain Housekeepers Start Moonlighting for the Tumor

When Brain Housekeepers Start Moonlighting for the Tumor

Help wanted: Star-shaped brain cell seeks flexible role in neighborhood management. Duties include feeding neurons, keeping the blood-brain barrier tidy, and, under unfortunate management, helping a tumor tell the immune system to take a very long coffee break.

May 02, 2026

Abexinostat: The Pill That Tells Cancer to Read Its Own Instruction Manual Again

Abexinostat: The Pill That Tells Cancer to Read Its Own Instruction Manual Again

Things follicular lymphoma cells are good at: dodging the immune system, staging comebacks after treatment, and - apparently - ignoring the genetic instruction manual that's supposed to keep them from going rogue. A new drug called abexinostat is here to fix that last one, and the results are...

May 02, 2026

Remission Is Not the End Credits

Remission Is Not the End Credits

Hodgkin lymphoma has one of the better reputations in cancer medicine, which sounds nice until you realize "better reputation" can hide a lot of mess. Cure rates are high. Treatments keep improving. Doctors have gotten much better at knocking the disease down. But this new Danish study asks the...